Synapse
⌘+K
Synapse
PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
August 6, 2025Advances in TherapyOpen Access

Comparative Effectiveness of Ciltacabtagene Autoleucel in CARTITUDE-4 Versus Real-World Physician’s Choice of Therapy from the Flatiron Registry in Lenalidomide-Refractory Multiple Myeloma

View Full Paper
Ask AI
Bookmark
Share

Authors

CTCyrille TouzeauBLBrea LipeAKAbdullah Khan

Discussion

Loading...

Member takes

Overview

Indirection treatment comparison shows improved PFS and OS in lenalidomide-refractory multiple myeloma with cilta-cel versus real-world choices, indicating significant benefits.

Key Points

  • Ciltacabtagene autoleucel showed significantly improved progression-free survival in lenalidomide-refractory multiple myeloma patients.
  • Hazard ratios reveal improved outcomes with cilta-cel: PFS HR 0.29 and OS HR 0.59, indicating substantial treatment benefits.
  • Comparative effectiveness was assessed through real-world data from the Flatiron registry and outcomes matched to CARTITUDE-4 criteria.
  • These findings underline cilta-cel's role as an effective option for patients with challenging multiple myeloma after prior therapies.

Cite This Study

Touzeau et al. (2025) studied this question.

synapsesocial.com/papers/689522189f4f1c896c429d0bhttps://doi.org/10.1007/s12325-025-03308-2
View Full Paper
Ask AI
Bookmark
Share